Zealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Update

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the recipient of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 1,241,700 shares, a decrease of 31.5% from the February 28th total of 1,811,500 shares. Currently, 1.7% of the company’s shares are sold short. Based on an average daily volume of 3,600 shares, the short-interest ratio is currently 344.9 days.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, January 21st. William Blair upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Friday, March 7th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $76.10 on Friday. The firm has a market cap of $5.40 billion, a P/E ratio of -32.25 and a beta of 0.92. Zealand Pharma A/S has a twelve month low of $71.20 and a twelve month high of $141.74. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. The firm’s 50 day moving average price is $94.15 and its two-hundred day moving average price is $105.84.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.19. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. On average, analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.